Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

Teens Innovate Lyme Disease Research with CRISPR Technology

CRISPR technology, a revolutionary tool in genetic engineering, has empowered Lambert's iGEM team to tackle a significant health issue: Lyme disease, which affects nearly half a million Americans ...

Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

12 Best Short Squeeze Stocks to Buy Right Now

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant ...

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.

3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential

These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the ...
Nature

How to fix genetic ‘nonsense’: versatile gene-editing tool could tackle a host of diseases

A single multipurpose gene-editing tool can correct several genetic conditions by restoring proteins that have been truncated ...